Medicina: Ematologia: Talassemie e trapianto del midollo osseo
| English |
| iron overload |
  |
|
| Attestation |
3
|
| Part of speech |
Noun syntagm
|
| Grammatical label |
Uncountable
|
| Definition |
The prime goal of iron-chelation therapy in patients with thalassemia-both major and intermedia is optimal control of body iron. The optimal body iron should minimize both the risk of adverse effects from iron-chelating therapy and the risk of complications from iron overload.Iron overload is the result of abnormal regulation of iron absorption resulting in an inappropriate increase in iron uptake. The minor degree of iron loading that develops in about one-quarter of patients who are heterozygotic for hereditary hemochromatosis appears to be associated with normal life expectancy. By contrast, patients who are homozygotic for the disorder develop greater iron burdens and have an increased risk of cardiac disease, liver fibrosis, diabetes mellitus, endocrine abnormalities, and other complications of iron overload.
|
| Definition source |
AA.VV. (1997). ‘Thalassemia Intermedia. A Region I Conference’. The Genetic Resource Special Issue, 1997, Volume 11, Number 2 (COSCEN01)
|
| Context |
Thalassemia patients can be categorized as class 1 (minimal liver damage and iron overload), class 3 (extensive liver damage from iron overload), and class 2 (intermediate). These categories are prognostic for treatment outcome after marrow transplantation.
|
| Context source |
Lucarelli, G., et al. (1996). ‘Marrow transplantation for patients with thalassemia: results in class 3 patients’. Blood 87(5):2082-8. (RISCEN78)
|
| Subject field |
Haemopoiesis
|
| Sub-field (level 1) |
Thalassemias
|
| Sub-field (level 2) |
Therapies
|
| Specific concept |
Hemosiderosis, hemochromatosis, liver siderosis
|
| Related concept |
Transfusional therapy, iron-chelation therapy, iron-chelating agent, desferrioxamine, deferiprone, HES-DFO, hepatosplenomegaly, splenectomy
|
| it |
Sovraccarico marziale
|
| Reliability code |
3
|
|
